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Background. The binding of the T cell receptor (TCR) to major histocompatibility complex (MHC) molecules in the thymus
determines fates of TCRab lymphocytes that subsequently home to secondary lymphoid tissue. TCR transgenic models have
been used to study thymic selection and lineage commitment. Most TCR transgenic mice express the rearranged TCRab
prematurely at the double negative stage and abnormal TCRab populations of T cells that are not easily detected in non-
transgenic mice have been found in secondary lymphoid tissue of TCR transgenic mice. Methodology and Principal Findings.
To determine developmental pathways of TCR-transgenic thymocytes, we used Cre-LoxP-mediated fate mapping and show
here that premature expression of a transgenic TCRab diverts some developing thymocytes to a developmental pathway which
resembles that of gamma delta cells. We found that most peripheral T cells with the HY-TCR in male mice have bypassed the
RORct-positive CD4
+8
+ (double positive, DP) stage to accumulate either as CD4
28
2 (double negative, DN) or as CD8a
+ T cells in
lymph nodes or gut epithelium. Likewise, DN TCRab cells in lymphoid tissue of female mice were not derived from DP
thymocytes. Conclusion. The results further support the hypothesis that the premature expression of the TCRab can divert DN
thymocytes into gamma delta lineage cells.
Citation: Egawa T, Kreslavsky T, Littman DR, von Boehmer H (2008) Lineage Diversion of T Cell Receptor Transgenic Thymocytes Revealed by Lineage
Fate Mapping. PLoS ONE 3(1): e1512. doi:10.1371/journal.pone.0001512
INTRODUCTION
‘‘HY transgenic’’ mice express a transgenic T cell receptor (TCR)
specific for HY antigen, i.e. a peptide of the Dby protein presented
by class I D
b MHC molecules. In male transgenic mice, CD4
+8
+
double positive (DP) cells undergo negative selection by TCR
agonist ligands and die by apoptosis [1]. However, CD8
+ cells
expressing mostly CD8a and low levels of CD8b as well as double
negative (DN) cells with the transgenic TCR are present among
extrathymic lymphocytes and intraepithelial gut lymphocytes (IEL)
in male HY transgenic mice [2]. In fact, CD8
+ cells with the
transgenic TCR represent the most abundant population of T cells
in the gut of these mice [3]. Two competing hypotheses with
regard to the origin of these extrathymic cells have been put
forward: one suggested that these cells survived the negative
selection process at the DP stage of thymocyte development by
down-regulating CD8 and CD4 co-receptor expression [4]. This
hypothesis appeared consistent with later experiments showing
that in vitro fetal thymic organ culture some DP cells from female
HY-TCR transgenic mice could become CD8aa T cells when
confronted with HY antigen [5]. Furthermore, our previous fate
mapping experiments indicated that in wild-type (WT) mice
CD8aa IEL with TCRab are derived from precursors expressing
RORct, which is an isoform of an orphan nuclear receptor,
RORc, encoded by the Rorc gene [6]. RORct is specifically
expressed in DP thymocytes. IEL with TCRcd expression are not
derived from RORct expressing precursors. This led to the
assumption that in WT and TCR transgenic mice CD8
+ IEL are
derived from DP thymocytes and that this pathway of differen-
tiation represents induction of a lineage away from conventional
TCRab cells that home to secondary lymphoid organs and
towards intestinal intraepithelial TCRab lymphocytes that may
have an important role in regulating gut immunity [7].
The competing hypothesis was that the CD8
+ and DN cells
expressing the HY transgenic TCR in male mice represent an
abnormal subset of cd lineage cells misguided by the premature
expression of the transgenic TCRab that would mimic signals
delivered normally by the TCRcd. In addition, it was postulated
that the confrontation of DN cells with the HY agonist ligand led
to expression of the CD8a co-receptor as is observed with some
activated TCRcd cells [2]. Consistent with the second hypothesis
was the observation that in mice exhibiting timely expression of
the HY transgenic TCR, i.e. at the CD4
+8
+ stage of development,
CD8aa IEL in the gut of male mice were much reduced [8]
arguing that abnormally early expression of this particular
transgenic TCR was indeed responsible for the generation of
CD8
+ IEL in male HY transgenic mice. Also, DN cells with the
HY-TCR could be observed in the periphery of female mice
indicating that a TCR agonist ligand was not required for their
generation [1].
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extrathymic lymphocytes with the HY receptor are derived from
RORct-positive DP precursors. By using RORct-dependent
lineage fate mapping in HY-TCR transgenic mice, it is therefore
possible to determine which of the models provides an adequate
explanation for how these cells are derived. RORct is an orphan
nuclear receptor, whose expression during T cell development
begins in late DN cells and is mostly restricted to DP thymocytes
[9,10]. Lineage fate mapping using bacterial artificial chromosome
(BAC) transgenic mice in which cre-recombinase is controlled by
RORct regulatory elements irreversibly labels cells developing
through the conventional CD4
+8
+ TCRab, but not the DN
TCRcd, pathway. Moreover, IEL do not express RORct [11].
Thus, breeding of the RORct-cre mice to mice bearing a loxP
flanked stop cassette in front of enhanced yellow fluorescent
protein (EYFP) embedded in the Rosa26 locus results in fluorescent
labeling of all RORct
+ precursor-derived T cells [6,12]. We
showed that all TCRab cells in the secondary lymphoid organs of
WT mice were labeled by RORct-cre and that non-conventional
TCRab populations of CD8aaTCRab IEL and Va14i natural
killer T (NKT) cells were likewise selected from a common pool of
RORct
+ precursors [6,13]. Utilizing this approach we have found
that both of the original hypotheses concerning non-conventional
TCRab cells in HY transgenic mice may be correct: the majority
of intraepithelial CD8aa cells in the gut of male HY-TCR
transgenic mice was derived from RORct-negative precursors
while a minority of HY-TCR
+ CD8aa cells in male mice and all
CD8aa cells in WT mice are derived from RORct-positive
precursor cells. Thus induction of the CD8aaTCRab lineage at
the RORct
+ stage of development occurs in both WT and TCR
transgenic mice whereas the precocious expression of a TCRab in
TCR transgenic mice generates subsets of misguided TCRab-
expressing T cells that are only rarely observed in normal mice.
RESULTS
Origin of non-transgenic T cells with diverse ab and
cdTCRs in WT and TCR transgenic mice
In RORct-cre;ROSA26-stop-EYFP mice on a non-TCR trans-
genic background, practically all extrathymic cells with surface
TCRb chains were EYFP
+ and thus derived from RORct
+ cells
such as DP thymocytes (Figure 1). The same EYFP expression
pattern was observed in extrathymic T cells from lymph nodes of
male and female HY-TCR transgenic mice that did not express
the transgenic TCR because of replacement of transgenic TCRa
by endogenous TCRa chains (Figure 1) [14,15]. This indicates
that, after endogenous TCRa rearrangement in TCR transgenic
mice, cells with new TCRs composed of transgenic TCRb chain
and endogenous TCRa chains develop in a similar pathway as
they do in normal mice. Cells with the phenotype of extrathymic T
cells were also found intrathymically (Figure S1) making it likely
that they are all derived from RORct
+ DP thymocytes. Thus, in
Figure 1. Fate mapping of T cells from WT and HY-TCR transgenic mice expressing endogenous TCRa using RORct-cre. CD4 and CD8a expression by
gated HY (T3.70)
2 TCRb
+ lymph node cells (left column) is shown in the second column. EYFP expression by HY
2CD4
+ and HY
2CD8a
+ T cells is shown.
doi:10.1371/journal.pone.0001512.g001
Fate Mapping of HY-TCR T Cells
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male mice, some cells develop normally if they escape deletion by
the early expression of endogenous TCRa chains.
The pattern of reporter expression observed in IEL bearing
endogenous TCRa chains was very similar to that obtained in
lymph node T cells, with the exception that IEL contained a high
proportion of CD8aa cells with TCRab that, like CD8ab IEL,
were EYFP
+ (Figure 2). These results confirm earlier data on IEL
in WT mice and in addition indicate that in TCR transgenic mice
IEL with receptors other than the transgenic TCR are derived
from RORct
+ precursors, presumably DP thymocytes. In contrast,
the vast majority of IEL with TCRcd was EYFP-negative in WT
as well as in TCR transgenic mice (Figures 2 and S3). Thus, T cells
with receptors other than the HY transgenic TCR, while they are
relatively rare in TCR transgenic mice, develop along the same
pathway as T cells in WT mice, indicating that normal pathways
of T cell differentiation are operative in TCR transgenic mice.
Origin of T cells with the transgenic HY TCR
In female HY TCR transgenic mice, single positive thymocytes
and lymph node T cells that express the transgenic TCR and either
CD4 or CD8 co-receptor were all EYFP-positive and thus derived
from DP thymocytes (Figures 3 and S2). The CD4
+ subset includes
cells with relatively high levels of the transgenic TCR. However, the
generationofthesecellsrequiresco-expressionofendogenousTCRa
chains since such CD4
+8
2 T cells are absent in female HY TCR
transgenic mice on the RAG-2
2/2 background [16]. In contrast to
WT mice, there was a substantial number of DN cells that expressed
TCRab in female transgenic mice. The vast majority of these cells
was EYFP-negative and thus was not derived from DP thymocytes.
TCRab-expressing DN cells were also detected intrathymically
(Figure S2). In male HY-TCR transgenic mice, T cells with the
transgenic TCR exhibited an even more abnormal phenotypic
pattern: the vast majority of DN cells and CD8
+ cells, the latter
expressing relatively low levels of CD8b, were EYFP-negative and
hence were not derived from DP thymocytes.
Similar abnormalities were noted in IEL, among which DN cells
comprised a much larger compartment in female HY-TCR
transgenic compared to WT mice (Figure 4); the majority of DN
cells with the transgenic TCR did not develop through RORct-
expressing DP thymocytes, similar to most CD8aa cells that were
likewise mostly EYFP-negative. However, in female mice, a
substantial number of EYFP-positive cells was also present among
HY
+ IEL that were either DN or CD8aa suggesting that induction
of these atypical lineages could have occurred at the DP stage. In
contrast, all CD8ab-positive cells with the transgenic TCR were
RORct
+ cell-derived. In male HY-TCR transgenic mice,
practically all DN, CD8aa and a majority of CD8ab cells were
EYFP-negative and hence were not derived from RORct
+ DP
thymocytes. This was especially true for the exaggerated number
of CD8aa IEL that in WT mice were all derived from RORct
+
precursors (Figures 2 and 4). The notion that most CD8a
+ HY-
TCR-expressing cells in IEL have a different origin than CD8a
+
IEL of WT mice is supported by the finding that only the former
expressed uniformly low levels of CD5 (data not shown).
Initial studies suggested that the abnormal DN and CD8
+ cells
with the HY transgenic TCR have similarities with gamma delta
lineage cells because, in contrast to conventional TCRab cells, they
had retained the germline TCRd (Tcrd)l o c u s[ 1 7 ] .T of u r t h e r
determine whether premature TCRab signals could induce a
signature gene for the TCRcd lineage, we purified thymic
subpopulations from HY-TCR transgenic mice or WT mice and
Figure 2. Fate mapping of IEL from WT and HY-TCR transgenic mice expressing endogenous TCRa using RORct-cre. CD4 and CD8a expression by
gated HY (T3.70)
2 TCRb
+ IEL (left column) is shown in the second column. CD8b expression by gated CD8a
+ cells (second column) is shown in the
third column. EYFP expression by HY
2CD4
+,H Y
2CD8aa
+ and HY
2CD8ab
+ T cells is shown.
doi:10.1371/journal.pone.0001512.g002
Fate Mapping of HY-TCR T Cells
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tothe developmentofTCRcdcells [18] (Figure5).Wecould observe
upregulation of Sox13 in TCRcd
+CD24
+CD25
+ thymocytes as
compared to DN2 thymocytes or TCRcd
2 DN3 thymocytes, and
Sox13 was further upregulated in TCRcd
+CD24
+CD25
2 thymo-
cytes (Figure 5A). However, Sox13 expression was then downreg-
ulated in TCRcd
+CD24
lo thymocytes and it became almost
undetectable in TCRcd
+ IEL, while Sox13 expression was barely
detected in TCRcd
2 DN4 or DP thymocytes which are selected
from DN3 precursors by pre-TCR signals (Figure 5A and 5B; data
not shown). These results suggest that Sox13 is transiently
upregulated following signals through TCRcd,b u tn o tp r e - T C R ,
attheDNthymocytestageandmayplaysomeroleinspecificationof
the TCRcd lineage [18]. In thymocytes from male HY mice, we
could observe significant upregulation of Sox13 in HY
+DN
thymocytes.SimilartoWTTCRcdlineagecells,Sox13upregulation
was detected at the CD25
+CD24
+ stage and peaked at the
CD25
2CD24
+ stage followed by Sox13 downregulation as cells
matured. These findings strongly support our hypothesis that
premature TCRab signals divert a proportion of TCRab
+ DN
thymocytes into the TCRcd lineage.
DISCUSSION
Most TCR transgenic mice express the transgenic TCRab at the
DN stage of T cell development and thus earlier than the
Figure 3. Fate mapping of lymph node T cells with the transgenic HY-TCR using RORct-cre. CD4 and CD8a expression by gated HY (T3.70)
+ lymph
node cells (left column) is shown in the second column. EYFP expression by HY
+CD4
2CD8a
2,H Y
+CD4
+CD8a
2 and HY
+CD4
2CD8a
+ T cells is shown.
doi:10.1371/journal.pone.0001512.g003
Figure 4. Fate mapping of IEL T cells with the transgenic HY-TCR using RORct-cre. CD4 and CD8a expression by gated HY (T3.70)
+ IEL (left column)
is shown in the second column. CD8b expression by gated CD8a
+ cells (second column) is shown in the third column. EYFP expression by
HY
+CD4
2CD8a
2,H Y
+CD4
+,H Y
+CD8aa
+ and HY
+CD8ab
+ T cells is shown.
doi:10.1371/journal.pone.0001512.g004
Fate Mapping of HY-TCR T Cells
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when normal regulatory elements of the Tcra and Tcrb genes have
been used, such as in HY transgenic mice; in these mice, cosmids
containing rearranged TCR genes were introduced and TCRb
and TCRa transgenes were integrated in tandem such that
expression of the TCRa transgenes can be regulated by Tcrb
control elements. Because of the premature TCRab expression,
the validity of conclusions obtained in TCR transgenic mice has
sometimes been questioned. A good example is the deletion of DP
thymocytes in HY transgenic mice, whose physiological relevance
was questioned by either assuming that the virtual absence of DP
thymocytes in male HY-TCR transgenic mice was not caused by
deletion but by a developmental arrest at the DN stage [19] or by
arguing that the too early TCR expression in the DP compartment
was responsible for deletion that normally would only occur in the
medulla [8]. One of us has previously explained why these
assumptions are unlikely to be true: DP cells are observed in the
thymus of male HY-TCR transgenic mice and are increased in
mice that lack CD8b co-receptor chains [20,21], arguing against a
developmental arrest at the DN stage as the sole explanation for
the low proportion of DP thymocytes in these mice. These studies,
together with another study using transgenic mice expressing a
mutant D
b molecule [21], suggest that interaction of MHC class I
and the CD8ab/TCRab complex is important for efficient
depletion of DP thymocytes in male HY mice. DP thymocyte
deletion also occurs in male HY-TCR transgenic mice with timely
onset of TCR transgene expression at the DP stage [8]. In
addition, studies in WT and TCR transgenic mice show that
ligation of the TCR on DP thymocytes results in their deletion
[22]. Thus, there is convincing evidence that DP thymocytes are
generally susceptible to deletion depending on the availability of
appropriately presented antigen in the thymic cortex, especially
class I MHC presented peptides derived from proteins such as HY
antigen [23], and that deletion of DP thymocytes in TCR
transgenic mice is representative of this physiological process.
The above considerations are important for the results
presented here since it is believed that confrontation of DP
thymocytes with cognate TCR ligands can result not only in
deletion, but also in induction of development of alternative
lineages, thereby generating T cells that can migrate from the
thymus and regulate immunity in the gut as CD8aa T cells [7].
Since these conclusions were reached from studies that included
experiments with TCR transgenic mice [5], careful consideration
has to be given to the possibility that results may have been
influenced by precocious expression of the TCRab in TCR
transgenic mice. With regard to this issue, it is important to
consider that in male HY transgenic mice CD8
+ T cells with the
transgenic TCR are present in peripheral lymphoid tissues and in
IEL, in spite of the fact that the cortex is largely devoid of DP
thymocytes. Two different scenarios were proposed to account for
these observations: in one scenario, down-modulation of CD8b co-
receptor at the DP stage was held responsible for the escape of T
cells into the periphery [4] while in the other it was assumed that
the CD8
+ cells were generated through activation of a differen-
tiation program for DN cd lineage cells that express the transgenic
TCRab, resulting in increased levels of CD8a [2].
The different hypotheses can be tested by using lineage fate
mapping that can distinguish whether subsets of T cells develop
through the RORct
+ stage or are derived directly from RORct-
negative precursors. The lineage fate mapping method utilized
here had previously been employed to trace the origin of CD8aa
cells in the gut and invariant NKT cells [6,13]. Using the same
approach in female and male HY-TCR transgenic mice, we have
now delineated the origin of various peripheral T cells in lymph
node and gut epithelium. The results do in fact show that the vast
majority of lymph node T cells and IEL with the HY transgenic
TCR and low level or no expression of CD8 co-receptors are
lineage diverted most likely at the DN stage of thymocyte
development before expression of RORct sets in, and are thus
independent of the DP thymocyte differentiation pathway. This
hypothesis is also supported by studies using CD8b deficient mice or
mice with a mutant MHC class I molecule [20,21]. Although
effective depletion of DP thymocytes relies on interaction of CD8ab
and the MHC class I molecule, accumulation of HY
+ DN
thymocytes was observed in CD8b deficient mice or in transgenic
mice bearing a mutant D
b molecule, in which substantially large
numbers of DP cells escape from deletion. These results suggest that
the lineage diversion of HY
+ DN cells does not require CD8ab/
MHC interaction and may take place independently of the DP stage
in which the majority of HY
+ cells are deleted. This conclusion
applies to most, but not all, of the CD8aa cells in IEL, especially in
malemice.In TCR transgenicmice,thesecells aredependenton the
premature expression of the transgenic TCRab in DN thymocytes
and hence represent an artificially exaggerated population of cells
that exists at a very low frequency in normal mice [24].
The few EYFP-labeled CD8aa cells with the transgenic TCR in
male HY transgenic mice may be generated through the DP
thymocyte stage, similarly to non-transgenic CD8aaTCRab IEL
Figure 5. Sox13 expression in thymocyte subpopulations from HY
transgenic mice. (A) Sox13 expression in male HY
+ DN thymocyte
subpopulations, WT DN thymocyte subpopulations and TCRcd
+
thymocyte subsets was determined by real time PCR. (B) Sox13
expression in peripheral T lymphocytes from WT and male HY
transgenic mice. As a reference, Sox13 expression in TCRcd
+ CD24
hi
thymocytes, which was detected in the same real time PCR
measurement, is shown together with Sox13 expression in peripheral
lymphocyte populations. Relative Sox13 expression levels normalized
against Hprt expression are shown. The data shown are representative
from two experiments with similar results.
doi:10.1371/journal.pone.0001512.g005
Fate Mapping of HY-TCR T Cells
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develop through the confrontation with TCR agonist ligands at
the DP stage: EYFP-positive CD8aa cells with relatively high
levels of the HY transgenic TCR are also found among IEL in
female transgenic mice where the HY ligand is not present.
However, it cannot be excluded that these cells also express
endogenous TCR chains and hence may have encountered TCR
agonist ligands intrathymically. The expression of endogenous
TCRa chains cannot, however, explain the existence of EYFP-
negative CD8aa IEL in female mice, since endogenous TCRa
expression at the DN thymocyte stage is a rather rare event. These
cells may express CD8a independently of cognate TCR ligands,
perhaps facilitated by the gut microenvironment. We also do not
completely rule out the possibility that a few EYFP-positive HY
+
cells or EYFP
+TCRcd cells might turn on RORct expression in
the lamina propria, where some T cells express RORct [11], and
then migrate to the epithelium.
It is of interest to note that all extrathymic T cells in TCR
transgenic mice that do not express the transgenic TCR exhibit the
same EYFP labeling pattern as extrathymic T cells in WT mice, i.e.
the TCRtransgenesdo not lead tomajorchangesinlymphoidorgan
structure that prevent normal lymphocyte development.
In summary these studies suggest that consequences of premature
TCRab expression have to be considered when analyzing pathways
of lymphocyte subset generation. It had previously been argued that
signals from the prematurely expressed TCRab may ‘‘fool’’ DN cells
to develop into cd lineage cells, including DN and CD8
+ cells in
lymph nodes and gut [2]. The lineage fate mapping studies reported
here supportthis scenario. Our conclusion is further strengthened by
our data demonstrating that Sox13 was upregulated in HY
+ DN
thymocytes following premature signals through TCRab instead of
pre-TCR, as is by other reports showing that these abnormal cells
exhibit profiles of surface marker and cytokine expression, which
resemble those of TCRcd cells rather than those of conventional
TCRab cells [18,25].
MATERIALS AND METHODS
Mice
HY TCR transgenic mice [1] were either from the colony
maintained in the Dana Farber Cancer Institute or purchased
from Taconic. RORct-cre and ROSA26-stop-EYFP mice were
previously described [6,12]. Mice were maintained in specific
pathogen-free animal facilities at NYU School of Medicine, the
Memorial Sloan-Kettering Cancer Center, or the Dana Farber
Cancer Institute. Experiments were performed according to the
protocols approved by the Institutional Animal Care and Use
Committee at the individual institutes listed above.
Flow Cytometric Analysis
Intraepithelial lymphocytes were prepared by exposing gut mucosa
to 1 mMDTT inPBS with vigorous shaking for 10 minutesat room
temperature. Staining of surface antigens was performed as
described [13]. Antibodies except for anti-HY TCR (T3.70) were
purchased from eBioscience (San Diego, CA). Anti-HY TCR
antibody was provided by eBioscience. Dead cells were excluded by
DAPI staining. Data were collected with an LSRII cytometer (BD
Biosciences, San Jose, CA) using FACSDiva software and were
analyzed with Flowjo software (Tree Star Inc., Ashland, OR).
Real Time PCR Analysis
Thymocyte subsets and peripheral lymphocytes were sorted from
WTand HYTCRtransgenicmiceinthe Rag2-deficient background
using FACSAria (BD Biosciences). Total RNA was prepared using
the RNeasy kit (Qiagen) followed by DNase digestion (Qiagen).
cDNA was synthesized using Superscript II and Superscript III
reverse transcriptases by oligo(dT) priming (Invitrogen Life Tech-
nologies) according to the manufacturer’s recommendations.
Amounts of Sox13 and Hprt RNA were quantified by real time
PCR with SYBR Green. The primer sequences for Sox13 were
obtained from SuperArray (catalogue number PPM04782A-200).
Hprt primers were described previously [26].
SUPPORTING INFORMATION
Figure S1 Fate-mapping of thymocytes from WT and HY-TCR
transgenic mice expressing endogenous TCRa using RORct. CD4
and CD8a expression by gated HY(T3.70)
2 TCRb
hi thymocytes
(left column) is shown in the second column. EYFP expression by
HY
2CD4
28a
2, CD4
+8a
+, CD4
+8a
2 and CD4
28a
+subsets is
shown. (There were very few, if any, HY
2 TCRb
hi CD4
28
2 cells
in the thymus of HY transgenic female or male mice.)
Found at: doi:10.1371/journal.pone.0001512.s001 (3.03 MB TIF)
Figure S2 Fate mapping of thymocytes with the transgenic HY-
TCR using RORct-cre induced EYFP labeling. CD4 and CD8a
expression by gated HY(T3.70)
hi thymocytes (left column) is shown
in the second column. EYFP expression by CD4
28a
2, CD4
+8a
+,
CD4
+8a
2 and CD4
28a
+ subsets is shown.
Found at: doi:10.1371/journal.pone.0001512.s002 (2.34 MB TIF)
Figure S3 EYFP expression in TCRcd IEL from RORct-cre;
ROSA26-stop-EYFP mice. TCRcd positive IEL from WT and
male and female HY-TCR transgenic mice were gated (top) and
EYFP expression is shown (bottom).
Found at: doi:10.1371/journal.pone.0001512.s003 (0.69 MB TIF)
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